摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(氨基甲基)环己醇盐酸盐 | 1394042-77-3

中文名称
4-(氨基甲基)环己醇盐酸盐
中文别名
——
英文名称
4-aminomethyl-cyclohexanol hydrochloride
英文别名
cis-4-(Aminomethyl)cyclohexanol hydrochloride;4-(aminomethyl)cyclohexan-1-ol;hydrochloride
4-(氨基甲基)环己醇盐酸盐化学式
CAS
1394042-77-3
化学式
C7H15NO*ClH
mdl
MFCD22378685
分子量
165.663
InChiKey
DWWWGZSFABKRSP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    46.2
  • 氢给体数:
    3
  • 氢受体数:
    2

文献信息

  • [EN] BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLYL-MÉTHYLURÉE EN TANT QU'AGONISTES DU RÉCEPTEUR ALX
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2015019325A1
    公开(公告)日:2015-02-12
    The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.
    本发明涉及式(I)的苯并咪唑基甲基生物,其中n、D、E、R1、R2、R3、R4、R6、R7、R8和R9如描述中所定义,它们的制备以及它们作为药用活性化合物的用途。
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    申请人:Mjalli Adnan M. M.
    公开号:US20110201604A1
    公开(公告)日:2011-08-18
    Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    提供了替代融合咪唑生物、其制备方法、包含替代融合咪唑生物的药物组合物,以及在治疗炎症中使用的方法。这些替代融合咪唑生物可能控制血红素氧合酶的活性或数量,或者同时控制活性和数量。
  • SPIRO-OXINDOLE MDM2 ANTAGONISTS
    申请人:Wang Shaomeng
    公开号:US20120122947A1
    公开(公告)日:2012-05-17
    Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
    本文提供了关于药物化学领域的化合物、组合物和方法。这里提供的化合物和组合物涉及螺环氧吲哚,其作为p53和MDM2相互作用的拮抗剂,并且它们作为治疗癌症和其他疾病的药物的用途。
  • Heteroaryl compounds, compositions thereof, and methods of treatment therewith
    申请人:Mortensen Deborah Sue
    公开号:US20090023724A1
    公开(公告)日:2009-01-22
    Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    本文提供具有以下结构的杂环芳基化合物:其中R1,R2,L,X,Y,Z,Q,A和B的定义如下,包括有效量的杂环芳基化合物的组合物以及治疗或预防癌症,炎症状况,免疫状况,代谢状况以及通过抑制激酶通路可治疗或预防的状况的方法,包括向需要治疗的患者中给予有效量的杂环芳基化合物。
  • METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS
    申请人:Mortensen Deborah Sue
    公开号:US20110245245A1
    公开(公告)日:2011-10-06
    Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    本文提供了具有以下结构的杂环芳基化合物:其中R1、R2、L、X、Y、Z、Q、A和B的定义如下,包括有效量的杂环芳基化合物的组合物,并且治疗或预防癌症、炎症状况、免疫病状况、代谢病状况和通过抑制激酶途径可治疗或预防的病状况的方法包括向需要治疗的患者中施用有效量的杂环芳基化合物。
查看更多